Pcn103 - Predicted Treatment Costs and Savings Per Patient of Kanjinti® (Trastuzumab Biosimilar) vs. Subcutaneous (Sc) and Intravenous (Iv) Herceptin® and Other Trastuzumab Biosimilars in Italy

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.186
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

BioDrugs
MedicineBiotechnologyPharmacology
2014English

Pharmacoeconomic Study of Herceptin® (Trastuzumab) for Breast Cancer Patients

Pharmacoeconomics: theory and practice
2014English

Safety of Trastuzumab (Herceptin®) During Pregnancy: Two Case Reports

Cases Journal
2009English

Subcutaneous Administration of Rituximab (MabThera) and Trastuzumab (Herceptin) Using Hyaluronidase

British Journal of Cancer
Cancer ResearchOncology
2013English

Trastuzumab (Herceptin)

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2011English

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® With a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

BioDrugs
MedicineBiotechnologyPharmacology
2020English

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Trastuzumab Biosimilar on Track for Approval

Cancer Discovery
Oncology
2017English

Development of HER2-specific Humanized Antibody Herceptin (Trastuzumab).

Folia Pharmacologica Japonica
Pharmacology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy